Chemiluminescencross bone gla protein (BGP) for Automatic immunoassay analyzer in Bone Metabolism

Chemiluminescencross bone gla protein (BGP) for Automatic immunoassay analyzer in Bone Metabolism

^{【expected usage】}

^{This product is used to quantitatively detect the content of osteocalcin (BGP) in human serum in vitro.
Osteocalcin (Osteocalcin), also known as BoneG-Gla Protein (BGP), is an acidic protein, which is vitamin K-dependent and contains three γ-carboxyglutamic acid side chains , γ-carboxyglutamic acid in BGP is very important for its biological properties, and BGP can be combined with Ca2+ after carboxylation. BGP is one of the most abundant non-collagen bone proteins in bone, and is ubiquitous in all vertebrate bones and teeth. It accounts for about 25% of the total collagen in adult bone. Vitamin K is an indispensable substance for the synthesis of BGP, and its synthesis is regulated by 1,25(OH)2D3. The use of vitamin K antagonists can reduce the content of this protein in bone, but does not affect its proline content, nor does it affect the mechanical strength of bone. Osteocalcin is the most abundant non-collagen protein in bones and is synthesized into the blood by osteoblasts. The half-life in blood is 4~5min, which is the most sensitive and specific indicator reflecting the activity of osteoblasts. Osteocalcin values ​​vary with age and with changes in bone turnover rates. The faster the bone turnover rate, the higher the osteocalcin value, and vice versa.
In primary osteoporosis, postmenopausal osteoporosis is a high conversion type, so osteocalcin is significantly increased; senile osteoporosis is a low conversion type, so osteocalcin is not significantly increased. Therefore, it is possible to identify whether osteoporosis is high-conversion type or low-conversion type according to the changes of osteocalcin. It should be noted that osteocalcin is significantly elevated in hyperparathyroid osteoporosis. , The change of serum BGP concentration is of great significance to the clinical research on the pathogenesis of bone diseases and endocrine and metabolic bone diseases and the study of bone components.
The current clinical and laboratory determination methods for osteocalcin include enzyme-linked immunosorbent assay, colloidal gold method, fluorescence immunoassay, and chemiluminescence method.}

Serum Osteocalcin (BGP) Introduction:
Osteocalcin is synthesized and secreted by osteoblasts, which is relatively stable and is not affected by bone resorption factors.
Serum osteocalcin can be used to understand the activity state of osteoblasts, especially newly formed osteoblasts.
Osteocalcin values vary with age and with changes in bone turnover rates. The faster the bone turnover rate, the higher the osteocalcin value, and vice versa.
In primary osteoporosis, postmenopausal osteoporosis is a high conversion type, so osteocalcin is significantly increased; senile osteoporosis is a low conversion type, so osteocalcin is not significantly increased. Therefore, it is possible to identify whether osteoporosis is high-conversion type or low-conversion type according to the changes of osteocalcin. It should be noted that osteocalcin is significantly elevated in hyperparathyroid osteoporosis.

Serum osteocalcin (BGP) normal value:
4.8-10.2ug/L.

The clinical significance of serum osteocalcin (BGP):
Elevated: seen in bone synthesis, especially in the early stage of bone synthesis after bone injury, postmenopausal osteoporosis, hyperparathyroidism osteoporosis.

Zecen Biotech CO., LTD., founded in 2011, is a leading Chinese diagnostics manufacturer specializing in in-vitro diagnostics devices and reagents. Zecen focus on the Chemiluminescent immunoassay (CLIA) field. With all products CE marked, our market presence currently spreads from across China to other countries including India, Switzerland, Russia etc., Zecen is expanding its footprint to become a global brand.

Zecen is the only enterprise with independent intellectual property rights in the entire chemiluminescence industry chain in China, including reagent, instrument, magnetic microbead, and reagent raw material. Our current products include more than 100 assays, from thyroid, inflammation, diabetes, tumer markers, immune disorders, hormones to cardiac markers. Our ever-expanding test menu helps our customers and collaborators keep up with the demands of healthcare sector. Zecen is striving for innovation and perfection to deliver the best products to the customers.

As a manufacturer, Zecen provide the OEM, ODM and other customized service of all products. We have the core R&D centers and innovative ability to lay a solid foundation for developing the broadest range of CLIA analyzers and test menu. High-quality sales and after-sales links provide the more intimate service. The patent and CE certification give us the confident sending all over the world, and more than 50 companys in the requiement of customized and have a long term coorperation with Zecen.